Please use this identifier to cite or link to this item:
https://scholars.lib.ntu.edu.tw/handle/123456789/477715
Title:
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients